The investment community reported on August 16 that according to 36 krypton reports, Shikun Technology completed a new round of financing of 700 million yuan at the end of July. Investors include Goldman Sachs Asset Management, Chunhua Capital, Sequoia China, Yuanyi Capital, Jianjie Asia, Ruizhi Capital, WT Focus China Fund, and Future Innovation Fund.
This round of financing will be used for R&D investment in the “digital human body” platform, which will greatly cover major areas of acute and chronic diseases; continue to improve the digital heart, brain, chest, bone, and abdomen product matrices, and accelerate the development of artificial intelligence-assisted diagnosis and adjuvant treatment product lines for other “digital organs” to accelerate the implementation and application of the digital human body in the intelligent construction process of hospitals across the country.
According to information, Shikun Technology focuses on the AI medical imaging circuit and uses artificial intelligence to assist traditional manual film reading, saving doctors' energy and time and reducing misdiagnoses and missed diagnoses. Common medical images include CT, B-ultrasound, X-ray, nuclear magnetic resonance, cardiovascular imaging, Doppler ultrasound, etc. For basic clinical diagnosis and treatment, this step is essential, accounting for almost 90% of medical information.
“Approval difficulties” were a common problem faced by racetracks in the past. At one point, players “piled up” in the field of tuberculosis went out of business on a large scale. At this level, Shikun Technology relied on high-threshold technology to become the company with the absolute highest number of registration certificates on the racetrack. Currently, it holds more than ten medical device registration certificates, covering diseases in key parts of the heart, brain, lungs, and abdomen.
Passing the certification checkpoint, the racetrack ushered in a period of explosion with the help of both capital and policy. Currently, two companies have clearly submitted prospectus, and according to information, several companies are preparing to go public. On the eve of the listing wave, “technology stories” were settled into “sales data”, and commercialization was undoubtedly the focus of competition.
In the four years since its establishment, Shikun Technology has broken through from a “digital heart” and has built a “digital human body” intelligent imaging platform that includes the digital heart, brain, chest, bones, abdomen, etc. Among them, the coronary stenosis AI product was the first to obtain the NMPA Class III certificate and then obtained the EU MDR CE certificate, making it the only coronary AI to obtain both NMPA and CE certificates. At the same time, Shikun's pneumonia AI products were also the first to obtain the EU MDR CE certificate.